Antengene Corporation Limited (HKG:6996)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 2.29B -13.2% |
| Revenue (ttm) | 117.22M +14.6% |
| Net Income | -266.11M |
| EPS | -0.42 |
| Shares Out | 679.24M |
| PE Ratio | n/a |
| Forward PE | 7.09 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 367,000 |
| Open | 3.400 |
| Previous Close | 3.370 |
| Day's Range | 3.270 - 3.540 |
| 52-Week Range | 2.680 - 8.160 |
| Beta | 0.33 |
| Analysts | Hold |
| Price Target | 5.03 (+47.94%) |
| Earnings Date | Aug 21, 2026 |
About Antengene Corporation
Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company’s commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR inhibitor f... [Read more]
Financial Performance
In 2025, Antengene Corporation's revenue was 105.34 million, an increase of 14.56% compared to the previous year's 91.95 million. Losses were -239.13 million, -25.10% less than in 2024.
Financial numbers in CNY Financial StatementsAnalyst Summary
According to one analyst, the rating for 6996 stock is "Hold" and the 12-month stock price target is $5.03.
News
Antengene Corporation Earnings release: H2 2025
Antengene Corporation released its H2 2025 earnings on March 20, 2026, summarizing the period's financial results.
Antengene Corporation Slides: H2 2025
Antengene Corporation has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 20, 2026.
Antengene Corporation Annual report: H2 2025
Antengene Corporation has published its H2 2025 annual report on March 20, 2026.
Antengene Corporation Transcript: Status update
Announced a global licensing deal with UCB for ATG-201, securing $80 million upfront and up to $1.2 billion in milestones, with Antengene conducting initial phase I trials and UCB leading global development. The AnTenGager platform underpins a robust pipeline and supports future collaborations.
Antengene Corporation Press release: Status update
Antengene Corporation issued a press release on March 4, 2026, disclosing material business information to investors.
Antengene Corporation Slides: Status update
Antengene Corporation has posted slides in relation to its latest quarterly earnings report, which was published on March 4, 2026.
Antengene Secures Malaysian Approval For XPOVIO In Relapsed/Refractory DLBCL
(RTTNews) - Antengene Corporation Limited (6996.HK) announced that the Malaysian National Pharmaceutical Regulatory Agency has approved a supplemental New Drug Application (sNDA) for XPOVIO (selinexor...
Antengene: NMPA Approves IND Application For Phase Ib/II CLINCH-2 Study With ATG-022
(RTTNews) - Antengene Corporation Limited (6996.HK) announced that China National Medical Products Administration or NMPA has approved the investigational new drug application for the Phase Ib/II CLIN...
Antengene Corporation Quarterly report: H1 2025
Antengene Corporation has published its H1 2025 quarterly earnings report on August 22, 2025.
Antengene Corporation Earnings release: H1 2025
Antengene Corporation released its H1 2025 earnings on August 22, 2025, summarizing the period's financial results.
Antengene Corporation Slides: H1 2025
Antengene Corporation has posted slides in relation to its H1 2025 quarterly earnings report, which was published on August 22, 2025.
Antengene Corporation Press release: Study Update
Antengene Corporation issued a press release on August 19, 2025, disclosing material business information to investors.
Antengene Corporation Slides: Study Update
Antengene Corporation has posted slides in relation to its latest quarterly earnings report, which was published on August 19, 2025.